Montrouge, France, June 21, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, held today its Combined Shareholders' Meeting, which was chaired by Pierre-Henri Benhamou, the Company's Chairman and Chief Executive Officer.
At the Combined Meeting, the Company's shareholders approved all the resolutions submitted by the Board of Directors. These resolutions can be found on DBV's website in the "Investor Relations" section http://www.dbv-technologies.com/en/investor-relations
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
|DBV Technologies Contact|
|Susanna Mesa Senior Vice President, Strategy +1 212-271-0861 firstname.lastname@example.org|
| Erinn White, Centron PR +1 646-722-8822 email@example.com |
| Media Contacts, Europe Caroline Carmagnol, Alize RP - Relation Presse |
+33 (0)6 64 18 99 59
PDF Version http://hugin.info/156437/R/2022277/751339.pdf